What is Burning Rock Biotech's operating income?

Burning Rock Biotech's total operating income in 2025 was -$7.84 million, based on the following breakdown: Total Gross Profit: $57.62 million Total Operating Expenses: $65.46 million

Burning Rock Biotech (BNR) Financials

$10.69 -0.61 (-5.40%)

As of 04:00 PM Eastern

Compare

Annual Income Statements for Burning Rock Biotech

This table shows Burning Rock Biotech's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-34	-48	-73	-125	-141	-92	-47	-7.91
Consolidated Net Income / (Loss)	-26	-24	-63	-125	-141	-92	-47	-7.91
Net Income / (Loss) Continuing Operations	-26	-24	-63	-125	-141	-92	-47	-7.91
Total Pre-Tax Income	-26	-24	-63	-125	-141	-92	-47	-7.69
Total Operating Income	-23	-24	-63	-125	-142	-94	-49	-7.84
Total Gross Profit	20	39	48	57	55	51	50	58
Total Revenue	30	55	66	80	82	76	71	77
Operating Revenue	30	55	66	80	82	76	71	77
Total Cost of Revenue	11	16	18	23	27	25	21	20
Operating Cost of Revenue	11	16	18	23	27	25	21	20
Total Operating Expenses	43	64	112	182	197	145	99	65
Selling, General & Admin Expense	13	19	45	77	82	62	36	18
Marketing Expense	15	22	26	48	54	35	26	24
Research & Development Expense	15	23	41	58	61	49	32	24
Impairment Charge	-	-	-	-	0.00	0.00	4.81	0.00
Total Other Income / (Expense), net	-2.34	-0.01	0.80	0.20	1.62	2.54	2.30	0.15
Interest Expense	2.61	1.29	0.10	0.24	-0.01	0.00	0.00	0.00
Interest & Investment Income	0.19	1.60	0.93	0.54	1.36	2.53	1.67	1.15
Other Income / (Expense), net	0.07	-0.32	-0.04	-0.10	0.25	0.01	0.63	-1.00
Income Tax Expense	0.00	0.00	0.00	0.14	0.29	0.34	0.81	0.22
Basic Earnings per Share	($10.38)	($14.23)	($13.76)	($15.30)	($2.71)	($1.80)	($0.92)	($0.02)
Weighted Average Basic Shares Outstanding	22.38M	23.48M	68.63M	104.21M	103.91M	102.40M	102.94M	106.30M
Diluted Earnings per Share	($10.38)	($14.23)	($13.76)	($15.30)	($2.71)	($1.80)	($0.92)	($0.02)
Weighted Average Diluted Shares Outstanding	22.38M	23.48M	68.63M	104.21M	103.91M	102.40M	102.94M	106.30M
Weighted Average Basic & Diluted Shares Outstanding	22.38M	23.48M	17.32M	17.32M	103.12M	103.15M	108.01M	108.86M

No quarterly income statements for Burning Rock Biotech are available.

This table details how cash moves in and out of Burning Rock Biotech's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	5.90	0.42	281	-76	-75	-44	-13	-5.87
Net Cash From Operating Activities	-22	-33	-11	-75	-66	-36	-13	-4.07
Net Cash From Continuing Operating Activities	-22	-33	-11	-75	-66	-36	-13	-4.07
Net Income / (Loss) Continuing Operations	-26	-24	-63	-125	-141	-92	-47	-7.91
Consolidated Net Income / (Loss)	-26	-24	-63	-125	-141	-92	-47	-7.91
Depreciation Expense	3.59	4.50	5.12	7.50	18	19	7.15	3.11
Non-Cash Adjustments To Reconcile Net Income	1.03	5.49	25	43	55	44	33	8.91
Changes in Operating Assets and Liabilities, net	-0.45	-18	21	-0.24	1.38	-6.78	-5.80	-8.17
Net Cash From Investing Activities	15	-50	-17	13	-1.08	-1.31	-0.60	-0.63
Net Cash From Continuing Investing Activities	15	-50	-17	13	-1.08	-1.31	-0.60	-0.63
Purchase of Property, Plant & Equipment	-3.58	-6.17	-9.27	-32	-10	-1.14	-0.74	-0.75
Acquisitions	-0.02	-0.06	-0.61	-0.40	-0.03	-0.18	-0.08	0.00
Sale of Property, Plant & Equipment	0.02	0.01	0.10	0.09	0.35	0.01	0.21	0.12
Net Cash From Financing Activities	12	82	333	-8.30	-13	-6.88	-0.01	0.27
Net Cash From Continuing Financing Activities	12	82	333	-8.30	-13	-6.88	-0.01	0.27
Repayment of Debt	-1.63	-13	-5.98	-6.23	-0.34	0.00	0.00	-0.01
Issuance of Debt	14	2.11	3.57	-	-	0.00	0.00	0.29
Other Financing Activities, net	-0.37	-0.67	-0.64	-2.07	-12	-6.88	-0.01	0.00
Effect of Exchange Rate Changes	-0.02	0.84	-24	-5.81	5.32	0.54	0.51	-1.45
Cash Interest Paid	2.01	1.52	0.55	0.24	0.13	0.00	0.00	0.00
Cash Income Taxes Paid	-	0.00	0.00	0.17	0.01	0.00	0.00	0.00

No quarterly cash flow statements for Burning Rock Biotech are available.

This table presents Burning Rock Biotech's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	122	410	358	230	146	121	117
Total Current Assets	101	388	286	183	125	106	106
Cash & Equivalents	14	292	225	131	87	71	68
Restricted Cash	0.58	4.60	1.22	2.87	0.02	0.32	0.39
Accounts Receivable	24	17	21	16	18	21	24
Inventories, net	8.34	10	19	19	9.72	7.37	6.95
Other Current Assets	10	8.82	9.46	14	10	6.67	5.62
Plant, Property, & Equipment, net	13	17	51	37	19	6.46	4.45
Total Noncurrent Assets	1.88	4.29	21	11	3.38	8.43	7.25
Intangible Assets	0.05	0.53	0.81	0.29	0.14	0.06	0.04
Other Noncurrent Operating Assets	1.57	3.54	20	10	2.45	8.37	7.21
Total Liabilities & Shareholders' Equity	122	410	358	230	146	121	117
Total Liabilities	30	37	68	62	38	42	41
Total Current Liabilities	24	37	58	60	37	36	35
Short-Term Debt	6.37	6.47	0.37	-	-	0.00	0.03
Accounts Payable	1.77	5.46	9.90	7.39	2.54	4.62	5.83
Accrued Expenses	7.76	13	20	25	15	12	12
Customer Deposits	0.59	0.17	0.15	0.26	0.17	0.08	0.08
Current Deferred Revenue	7.11	11	22	21	18	16	15
Other Current Liabilities	-	0.74	5.49	5.40	1.22	3.37	2.40
Total Noncurrent Liabilities	3.46	0.08	9.59	2.56	1.16	5.23	5.45
Long-Term Debt	2.62	-	-	-	-	0.00	0.24
Other Noncurrent Operating Liabilities	0.14	0.08	9.59	2.56	1.16	5.23	5.21
Commitments & Contingencies	0.00	-	-	-	-	0.00	0.00
Total Equity & Noncontrolling Interests	-128	372	290	168	108	80	77
Total Preferred & Common Equity	-128	372	290	168	108	80	77
Total Common Equity	-128	372	290	168	108	80	77
Common Stock	6.56	616	672	664	683	685	716
Retained Earnings	-136	-218	-350	-464	-543	-575	-609
Treasury Stock	-	-	0.00	-8.54	-9.28	-8.67	-8.18
Accumulated Other Comprehensive Income / (Loss)	1.34	-26	-32	-24	-23	-22	-23

No quarterly balance sheets for Burning Rock Biotech are available.

This table displays calculated financial ratios and metrics derived from Burning Rock Biotech's official financial filings.

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	0.00	105,218,680.00	105,729,199.00	103,116,848.00	103,149,276.00	108,006,999.00	108,857,635.00
DEI Adjusted Shares Outstanding	0.00	0.00	10,521,868.00	10,572,920.00	10,311,685.00	10,314,928.00	108,006,999.00	108,857,635.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	0.00	-6.90	-11.82	-13.66	-8.93	-0.44	-0.07
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	80.26%	20.66%	20.53%	2.47%	-7.31%	-6.64%	9.18%
EBITDA Growth	0.00%	-1.37%	-190.32%	-101.71%	-5.29%	39.09%	45.41%	86.10%
EBIT Growth	0.00%	-5.05%	-158.00%	-97.24%	-13.36%	33.57%	48.70%	81.72%
NOPAT Growth	0.00%	-3.35%	-161.27%	-97.19%	-13.65%	33.68%	48.04%	83.99%
Net Income Growth	0.00%	5.99%	-157.90%	-99.60%	-12.64%	34.62%	48.42%	83.33%
EPS Growth	0.00%	-37.09%	3.30%	-11.19%	-12.64%	34.62%	48.62%	97.83%
Operating Cash Flow Growth	0.00%	-51.19%	65.45%	-562.97%	11.68%	45.61%	64.92%	67.82%
Free Cash Flow Firm Growth	0.00%	0.00%	43.47%	-260.11%	30.93%	32.06%	61.36%	73.69%
Invested Capital Growth	0.00%	0.00%	-31.88%	101.29%	-37.57%	-36.10%	-62.67%	-0.23%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	64.66%	71.61%	73.02%	71.70%	67.47%	67.59%	70.26%	74.67%
EBITDA Margin	-65.21%	-36.67%	-88.24%	-147.67%	-151.73%	-99.71%	-58.31%	-7.42%
Operating Margin	-77.27%	-44.30%	-95.93%	-156.95%	-174.07%	-124.54%	-69.32%	-10.16%
EBIT Margin	-77.03%	-44.89%	-95.98%	-157.07%	-173.76%	-124.53%	-68.43%	-11.46%
Profit (Net Income) Margin	-84.98%	-44.32%	-94.73%	-156.87%	-172.44%	-121.63%	-67.20%	-10.26%
Tax Burden Percent	100.00%	100.00%	100.00%	100.11%	100.20%	100.37%	101.73%	102.89%
Interest Burden Percent	110.33%	98.73%	98.69%	99.76%	99.03%	97.32%	96.54%	87.02%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-86.36%	-134.21%	-216.78%	-227.02%	-239.00%	-231.95%	-68.39%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-58.25%	-125.03%	-203.89%	-204.68%	-215.39%	-215.27%	-64.92%
Return on Net Nonoperating Assets (RNNOA)	0.00%	33.13%	107.19%	179.01%	165.47%	172.32%	181.38%	58.25%
Return on Equity (ROE)	0.00%	-53.23%	-27.02%	-37.77%	-61.56%	-66.68%	-50.57%	-10.14%
Cash Return on Invested Capital (CROIC)	0.00%	-286.36%	-96.28%	-284.02%	-180.77%	-194.95%	-140.68%	-68.16%
Operating Return on Assets (OROA)	0.00%	-20.21%	-23.89%	-32.64%	-48.29%	-50.05%	-36.12%	-7.41%
Return on Assets (ROA)	0.00%	-19.96%	-23.58%	-32.59%	-47.92%	-48.89%	-35.47%	-6.63%
Return on Common Equity (ROCE)	0.00%	74.67%	-14.24%	-37.77%	-61.56%	-66.68%	-50.57%	-10.14%
Return on Equity Simple (ROE_SIMPLE)	0.00%	18.97%	-16.82%	-43.17%	-83.85%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-16	-17	-44	-88	-100	-66	-34	-5.49
NOPAT Margin	-54.09%	-31.01%	-67.15%	-109.86%	-121.85%	-87.18%	-48.52%	-7.12%
Net Nonoperating Expense Percent (NNEP)	0.00%	-28.11%	-9.18%	-12.89%	-22.34%	-23.61%	-16.68%	-3.46%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-59.25%	-60.97%	-43.09%	-7.15%
Cost of Revenue to Revenue	35.34%	28.39%	26.98%	28.30%	32.53%	32.41%	29.74%	25.33%
SG&A Expenses to Revenue	42.28%	34.63%	68.34%	96.53%	100.90%	81.46%	50.72%	23.37%
R&D to Revenue	50.41%	41.12%	61.40%	72.43%	74.90%	64.57%	45.03%	30.86%
Operating Expenses to Revenue	141.93%	115.92%	168.95%	228.65%	241.54%	192.13%	139.58%	84.84%
Earnings before Interest and Taxes (EBIT)	-23	-25	-63	-125	-142	-94	-48	-8.84
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-20	-20	-58	-118	-124	-75	-41	-5.73
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	8.37	3.46	1.42	0.89	0.88	28.43
Price to Tangible Book Value (P/TBV)	0.00	0.00	8.39	3.47	1.42	0.89	0.88	28.45
Price to Revenue (P/Rev)	7.33	4.06	47.16	12.58	2.91	1.27	0.99	28.21
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	9.97	103.43	14.22	3.08	0.43	0.00	262.86
Enterprise Value to Revenue (EV/Rev)	0.00	7.16	41.94	9.63	1.27	0.12	0.00	27.32
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.11	0.02	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.04	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-0.57	-0.86	-0.88	-0.81	-0.80	-0.84	-0.90
Leverage Ratio	0.00	1.33	1.15	1.16	1.28	1.36	1.43	1.53
Compound Leverage Factor	0.00	1.32	1.13	1.16	1.27	1.33	1.38	1.33
Debt to Total Capital	0.00%	9.60%	1.71%	0.13%	0.00%	0.00%	0.00%	0.35%
Short-Term Debt to Total Capital	0.00%	6.31%	1.71%	0.13%	0.00%	0.00%	0.00%	0.04%
Long-Term Debt to Total Capital	0.00%	3.28%	0.00%	0.00%	0.00%	0.00%	0.00%	0.32%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	217.21%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-126.81%	98.29%	99.87%	100.00%	100.00%	100.00%	99.65%
Debt to EBITDA	0.00	-0.48	-0.11	0.00	0.00	0.00	0.00	-0.05
Net Debt to EBITDA	0.00	2.48	5.92	2.00	0.00	0.00	0.00	11.96
Long-Term Debt to EBITDA	0.00	-0.16	0.00	0.00	0.00	0.00	0.00	-0.04
Debt to NOPAT	0.00	-0.57	-0.15	0.00	0.00	0.00	0.00	-0.05
Net Debt to NOPAT	0.00	2.93	7.78	2.69	0.00	0.00	0.00	12.48
Long-Term Debt to NOPAT	0.00	-0.20	0.00	0.00	0.00	0.00	0.00	-0.04
Altman Z-Score	0.00	3.38	50.20	7.31	-1.57	-4.57	-5.68	25.89
Noncontrolling Interest Sharing Ratio	0.00%	240.27%	47.29%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	0.00	4.30	10.45	4.89	3.06	3.36	2.92	2.99
Quick Ratio	0.00	3.48	9.81	4.38	2.47	2.82	2.52	2.62
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-56	-32	-115	-79	-54	-21	-5.47
Operating Cash Flow to CapEx	-608.61%	-531.89%	-123.31%	-234.53%	-673.00%	-3,189.31%	-2,393.90%	-647.76%
Free Cash Flow to Firm to Interest Expense	0.00	-43.66	-310.50	-475.91	0.00	0.00	0.00	-1,275.45
Operating Cash Flow to Interest Expense	-8.29	-25.37	-110.26	-311.12	0.00	0.00	0.00	-948.10
Operating Cash Flow Less CapEx to Interest Expense	-9.65	-30.14	-199.67	-443.78	0.00	0.00	0.00	-1,094.47
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.45	0.25	0.21	0.28	0.40	0.53	0.65
Accounts Receivable Turnover	0.00	2.33	3.26	4.17	4.41	4.48	3.65	3.42
Inventory Turnover	0.00	1.86	1.90	1.51	1.39	1.71	2.46	2.73
Fixed Asset Turnover	0.00	4.27	4.41	2.34	1.86	2.75	5.64	14.15
Accounts Payable Turnover	0.00	8.77	4.93	2.94	3.07	4.94	5.87	3.74
Days Sales Outstanding (DSO)	0.00	156.93	112.14	87.45	82.83	81.51	99.93	106.63
Days Inventory Outstanding (DIO)	0.00	195.79	192.40	241.12	262.67	212.84	148.36	133.66
Days Payable Outstanding (DPO)	0.00	41.60	73.97	124.27	118.76	73.86	62.23	97.59
Cash Conversion Cycle (CCC)	0.00	311.12	230.56	204.30	226.73	220.49	186.06	142.70
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	0.00	39	27	54	34	22	8.04	8.02
Invested Capital Turnover	0.00	2.78	2.00	1.97	1.86	2.74	4.78	9.61
Increase / (Decrease) in Invested Capital	0.00	39	-13	27	-20	-12	-13	-0.02
Enterprise Value (EV)	0.00	392	2,773	767	104	9.20	-1.91	2,108
Market Capitalization	223	223	3,119	1,003	238	96	70	2,176
Book Value per Share	$0.00	($5.45)	$5.43	$2.75	$1.59	$1.05	$0.77	$0.71
Tangible Book Value per Share	$0.00	($5.45)	$5.42	$2.74	$1.59	$1.05	$0.77	$0.71
Total Capital	0.00	101	379	290	168	108	80	77
Total Debt	0.00	9.69	6.47	0.37	0.00	0.00	0.00	0.27
Total Long-Term Debt	0.00	3.31	0.00	0.00	0.00	0.00	0.00	0.24
Net Debt	0.00	-50	-346	-236	-134	-87	-72	-69
Capital Expenditures (CapEx)	3.56	6.16	9.17	32	9.84	1.13	0.53	0.63
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	25	5.67	-8.12	-11	0.78	-1.62	1.53
Debt-free Net Working Capital (DFNWC)	0.00	84	357	228	123	87	70	70
Net Working Capital (NWC)	0.00	78	351	227	123	87	70	70
Net Nonoperating Expense (NNE)	9.39	7.29	18	37	41	26	13	2.42
Net Nonoperating Obligations (NNO)	0.00	-52	-346	-236	-134	-87	-72	-69
Total Depreciation and Amortization (D&A)	3.59	4.50	5.12	7.50	18	19	7.15	3.11
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	45.72%	8.57%	-10.19%	-13.84%	1.03%	-2.30%	1.99%
Debt-free Net Working Capital to Revenue	0.00%	153.73%	540.63%	285.73%	150.44%	115.50%	98.93%	91.15%
Net Working Capital to Revenue	0.00%	142.10%	530.85%	285.27%	150.44%	115.50%	98.93%	91.11%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($21.00)	($24.00)	($27.20)	($18.00)	($0.13)	($0.02)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	10.52M	10.57M	10.39M	10.24M	102.94M	106.30M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($21.00)	($24.00)	($27.20)	($18.00)	($0.13)	($0.02)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	10.52M	10.57M	10.39M	10.24M	102.94M	106.30M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($21.00)	($24.00)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	6.86M	10.42M	10.31M	10.31M	108.01M	108.86M
Normalized Net Operating Profit after Tax (NOPAT)	-16	-17	-44	-88	-100	-66	-31	-5.49
Normalized NOPAT Margin	-54.09%	-31.01%	-67.15%	-109.86%	-121.85%	-87.18%	-43.76%	-7.12%
Pre Tax Income Margin	-84.98%	-44.32%	-94.73%	-156.70%	-172.09%	-121.19%	-66.06%	-9.97%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-8.96	-19.06	-618.64	-519.35	0.00	0.00	0.00	-2,060.43
NOPAT to Interest Expense	-6.29	-13.17	-432.81	-363.25	0.00	0.00	0.00	-1,279.72
EBIT Less CapEx to Interest Expense	-10.32	-23.83	-708.06	-652.01	0.00	0.00	0.00	-2,206.80
NOPAT Less CapEx to Interest Expense	-7.66	-17.94	-522.22	-495.90	0.00	0.00	0.00	-1,426.08
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-2.15%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

No quarterly metrics and ratios for Burning Rock Biotech are available.

Financials Breakdown Chart

Burning Rock Biotech Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Burning Rock Biotech's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Burning Rock Biotech's net income were at -$7.91 million at the end of 2025, a 83.3% decrease from 2024, and a 69.4% decrease since 2018. View Burning Rock Biotech's forecast to see where analysts expect Burning Rock Biotech to go next.

Burning Rock Biotech's total operating income in 2025 was -$7.84 million, based on the following breakdown:

Total Gross Profit: $57.62 million
Total Operating Expenses: $65.46 million

Over the last 7 years, Burning Rock Biotech's total revenue changed from $30.40 million in 2018 to $77.16 million in 2025, a change of 153.8%.

Burning Rock Biotech's total liabilities were at $40.77 million at the end of 2025, a 2.3% decrease from 2024, and a 33.9% increase since 2019.

In the past 6 years, Burning Rock Biotech's cash and equivalents has ranged from $13.53 million in 2019 to $291.51 million in 2020, and is currently $68.41 million as of their latest financial filing in 2025.

Over the last 7 years, Burning Rock Biotech's book value per share changed from 0.00 in 2018 to 0.71 in 2025, a change of 70.9%.

Related Companies

Financial statements for NASDAQ:BNR last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Burning Rock Biotech (BNR) Financials

Financials Breakdown Chart

Burning Rock Biotech Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Burning Rock Biotech (BNR) Financials

Annual Income Statements for Burning Rock Biotech

Quarterly Income Statements for Burning Rock Biotech

Annual Cash Flow Statements for Burning Rock Biotech

Quarterly Cash Flow Statements for Burning Rock Biotech

Annual Balance Sheets for Burning Rock Biotech

Quarterly Balance Sheets for Burning Rock Biotech

Annual Metrics And Ratios for Burning Rock Biotech

Quarterly Metrics And Ratios for Burning Rock Biotech

Financials Breakdown Chart

Burning Rock Biotech Financials - Frequently Asked Questions

When does Burning Rock Biotech's fiscal year end?

How has Burning Rock Biotech's net income changed over the last 7 years?

What is Burning Rock Biotech's operating income?

How has Burning Rock Biotech's revenue changed over the last 7 years?

How much debt does Burning Rock Biotech have?

How much cash does Burning Rock Biotech have?

How has Burning Rock Biotech's book value per share changed over the last 7 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools